ArticleFrontiers in endocrinology2026
Diagnostic efficacy of ([Ca]×[Cl])/P combined with ALP in the diagnosis and subtype differentiation of primary hyperparathyroidism.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the diagnostic performance of the calcium-chloride/phosphorus ratio (([Ca]×[Cl])/P) combined with alkaline phosphatase (ALP) in primary hyperparathyroidism (PHPT) and its subtypes-hypercalcemic PHPT (HPHPT) and normocalcemic PHPT (NPHPT)-for accurate clinical differentiation. Methods: Clinical data of 135 surgically confirmed patients with PHPT (77 HPHPT, 58 NPHPT) and 135 age- and sex-matched healthy controls from Taizhou Enze Medical Center (Jan 2017-Dec 2024) were retrospectively analyzed. Serum ALP, Ca/P, Cl/P, and ([Ca]×[Cl])/P were measured; ROC curves assessed the diagnostic performance of single and combined indicators. Results: Most patients with PHPT were female. Adenoma prevalence was higher in the HPHPT group (83.12%) than in the NPHPT group (60.34%). ALP, parathyroid hormone (PTH), Ca/P, Cl/P, and ([Ca]×[Cl])/P levels were elevated in the HPHPT group compared with both the NPHPT and control groups, while serum phosphorus was lower (P<0.001). The area under the ROC curve (AUC) for ([Ca]×[Cl])/P in diagnosing PHPT was 0.960. Combined detection of ([Ca]×[Cl])/P (250.67 mmol/L) and ALP (93.50 U/L) yielded an AUC of 0.983 (sensitivity: 94.8%, specificity: 98.5%, accuracy: 95.0%), comparable to that of PTH (AUC = 0.997). The AUC for differentiating HPHPT from NPHPT was 0.881, and for distinguishing adenomas from hyperplasia was 0.677, demonstrating superior subtype discrimination compared with other indicators, including PTH. Conclusion: The combination of ([Ca]×[Cl])/P and ALP demonstrates favorable sensitivity and specificity for the diagnosis of PHPT and the differentiation of HPHPT from NPHPT, and exhibits clinical practicality. In addition, it provides supplementary value in distinguishing parathyroid adenoma from hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.